Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,400.96
(
-0.16%
)
US TECH 100
28,206.80
(
-1.14%
)
Dow Jones
49,760.56
(
0.11%
)
Brent Oil
104.63
(
-1.07%
)
Bitcoin
81,035.55
(
0.68%
)
News Focus
News Focus
Post# of 347009
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (5) Keep Next 10 Report Keyboard Shortcuts
Replies (5) Next 10 Prev Next

Protector

Send PM Follow Ignore
Followers 140
Posts 11663
Boards Moderated 0
Alias Born 03/15/2011

Protector

Re: None

Thursday, 06/23/2016 10:56:43 AM

Thursday, June 23, 2016 10:56:43 AM

Post# of 347009
MERCK on board with PPHM's BAVITUXIMAB ?

On APR 21, 2016 NCCN writes about PPHM's Bavituximab trials :

Planned studies include bavituximab in combination with pembrolizumab in hepatocellular carcinoma, and durvalumab in NSCLC.



pembrolizumab = PD-1 = KEYTRUDA = MERCK !!!!!


source, public since 21 JUN 2016 - published today

Peregrine Pharmaceuticals the Microsoft of Biotechnology! All In My Opinion. I am not advising anything, nor accusing anyone.

Public Reply Private Reply New Post
Keep Last Read
Replies (5) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (5) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote